Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KLRSNASDAQ:KODNASDAQ:PROKNASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLRSKalaris Therapeutics$2.50-2.3%$0.00$2.28▼$24.15$47.88M0.4838,087 shs35,701 shsKODKodiak Sciences$3.96+3.4%$3.85$1.92▼$11.60$202.08M2.28346,467 shs311,539 shsPROKProKidney$0.69+19.1%$0.78$0.46▼$2.59N/A1.26700,626 shs1.54 million shsSLSSELLAS Life Sciences Group$2.18+2.6%$1.70$0.77▼$2.27$211.53M2.311.72 million shs1.40 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLRSKalaris Therapeutics-0.78%-1.54%-14.67%+255,999,900.00%+255,999,900.00%KODKodiak Sciences+1.86%+3.79%+6.39%+59.58%+70.98%PROKProKidney+2.39%-24.94%-22.42%-18.65%-74.17%SLSSELLAS Life Sciences Group+1.92%+14.59%+34.18%+92.73%+89.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKODKodiak Sciences4.3408 of 5 stars3.04.00.04.62.53.30.0PROKProKidney2.1099 of 5 stars3.00.00.00.02.34.20.6SLSSELLAS Life Sciences Group0.7571 of 5 stars0.01.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKLRSKalaris Therapeutics 0.00N/AN/AN/AKODKodiak Sciences 2.00Hold$9.00127.27% UpsidePROKProKidney 2.00Hold$3.50407.98% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KLRS, PROK, KOD, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/APROKProKidney$80K2,520.88N/AN/A($3.41) per share-0.20SLSSELLAS Life Sciences Group$1M217.02N/AN/A$0.13 per share16.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-62.08%-54.69%N/AKODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)SLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)Latest KLRS, PROK, KOD, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKLRSKalaris TherapeuticsN/A14.3114.31KODKodiak SciencesN/A4.624.62PROKProKidneyN/A10.9610.96SLSSELLAS Life Sciences GroupN/A4.644.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKLRSKalaris Therapeutics66.05%KODKodiak Sciences89.06%PROKProKidney51.59%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipKLRSKalaris Therapeutics32.07%KODKodiak Sciences45.90%PROKProKidney41.49%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKLRSKalaris Therapeutics11018.70 million12.70 millionN/AKODKodiak Sciences9052.76 million28.55 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableSLSSELLAS Life Sciences Group1099.78 million98.38 millionNot OptionableKLRS, PROK, KOD, and SLS HeadlinesRecent News About These CompaniesSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?June 23, 2025 | zacks.comSellas Life Sciences: Tons Of Completed StudiesJune 17, 2025 | seekingalpha.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short InterestJune 16, 2025 | marketbeat.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14, 2025 | insidertrades.comNostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 13, 2025 | marketbeat.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comSELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025June 4, 2025 | nasdaq.comInsider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of StockJune 3, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 SharesJune 3, 2025 | insidertrades.comSELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.comSELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common StockMay 16, 2025 | fxempire.comFSellas doses first paediatric subject with AML in Phase II trial of SLS009May 16, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | finanznachrichten.deSELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | globenewswire.comSELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025April 28, 2025 | quiverquant.comQSELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceApril 28, 2025 | globenewswire.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%April 26, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLRS, PROK, KOD, and SLS Company DescriptionsKalaris Therapeutics NASDAQ:KLRS$2.50 -0.06 (-2.34%) As of 01:00 PM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Kodiak Sciences NASDAQ:KOD$3.96 +0.13 (+3.39%) Closing price 03:35 PM EasternExtended Trading$3.89 -0.07 (-1.87%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.ProKidney NASDAQ:PROK$0.69 +0.11 (+19.06%) Closing price 03:57 PM EasternExtended Trading$0.69 0.00 (-0.44%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.SELLAS Life Sciences Group NASDAQ:SLS$2.17 +0.06 (+2.59%) Closing price 03:52 PM EasternExtended Trading$2.17 0.00 (-0.18%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
